Effect of procetofen on serum lipids and apoproteins.
The effect of procetofen (fenofibrate) on lipids and apoproteins was studied in ten patients affected with familial type II-A and II-B hyperlipoproteinemia. Following stabilization with an isocaloric diet for 2 months, the patients were given 300 mg/day of procetofen for 3 months, then placebo for 1 month. Plasma cholesterol and triglycerides were decreased by 15% and 46%, respectively. Plasma apo B was lowered by 17%. The predominant decrease in lipids and apoproteins occurred in VLDL, whereas in HDL cholesterol increased significantly but not its major apoprotein, apo A-I. A mechanism of action involving increased catabolism of VLDL and reduced synthesis of LDL and VLDL is proposed.
D000328:Adult; D001059:Apoproteins / Q000032:analysis / Q000097:blood; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000494:pharmacology*; D014280:Triglycerides / Q000032:analysis / Q000097:blood
D001059:Apoproteins; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011422:Propionates; D014280:Triglycerides; D002784:Cholesterol; D011345:Fenofibrate